Alternative therapeutic strategies being investigated to reduce mesothelial cell-mediated inflammation and prevent peritoneal fibrosis include targeting TGFβ1-mediated mechanisms (Hung et al., 2001, 2003; Yung et al., 2001; Margetts et al., 2002a; Fang et al., 2006; Tomino, 2012; Jang et al., 2013), reducing mesothelial cell production of fibronectin (Tong et al., 2012; Zhang et al., 2014) developing a more bio compatible PD solution (Bajo et al., 2000; Le Poole et al., 2005), altering PD daily dwelling time (Lee et al., 2014), and stimulating fibrinolytic agents (Haslinger et al., 2003). This evidence concerns the gene TGFB1 and Peritoneal Fibrosis.